Product
GA101
Aliases
Obinutuzumab
3 clinical trials
2 indications
Indication
Chronic lymphocytic leukemiaIndication
Chronic Lymphocytic LeukemiaClinical trial
A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and ABT-199 Followed by ABT-199 and GA101 Maintenance in CLL PatientsStatus: Active (not recruiting), Estimated PCD: 2016-12-13
Clinical trial
A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+IbrutinibStatus: Active (not recruiting), Estimated PCD: 2023-11-01